Lexicon Pharmaceuticals traded at $2.63 this Wednesday July 6th, decreasing $0.12 or 4.36 percent since the previous trading session. Looking back, over the last four weeks, Lexicon Pharmaceuticals lost 51.15 percent. Over the last 12 months, its price fell by 32.39 percent. Looking ahead, we forecast Lexicon Pharmaceuticals to be priced at 1.89 by the end of this quarter and at 1.74 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
2.64
Daily Change
0.38%
Yearly
-32.13%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Abbott 108.76 0.07 0.06% -8.80%
Acadia Pharmaceuticals 15.12 -0.15 -0.98% -36.92%
Acorda Therapeutics 0.45 -0.04 -7.31% -89.61%
Agios Pharmaceuticals 25.35 -0.10 -0.39% -55.38%
Akebia Therapeutics 0.46 0.05 12.47% -86.39%
Alnylam Pharmaceuticals 150.00 -0.73 -0.48% -13.09%
AstraZeneca 11,050.00 72.00 0.66% 28.65%
Bluebird Bio 4.82 -0.23 -4.55% -84.51%
BioMarin Pharmaceutical 86.41 0.05 0.06% 4.06%
Coherus Biosciences 8.88 0.34 3.98% -33.73%
Clovis Oncology 2.18 -0.23 -9.54% -59.55%
Esperion Therapeutics 6.68 -0.01 -0.13% -65.29%
Halozyme Therapeutics 47.07 0.32 0.68% 3.18%
Intercept Pharmaceuticals 13.85 -1.44 -9.42% -27.03%
Illumina 198.75 3.36 1.72% -58.02%
Insmed 22.93 0.87 3.94% -17.70%
Ironwood Pharmaceuticals 11.92 0.05 0.42% -3.09%
J&J 178.49 0.19 0.11% 5.57%
Eli Lilly 327.50 -2.65 -0.80% 38.12%
Lexicon Pharmaceuticals 2.64 0.01 0.38% -32.13%
MacroGenics 3.50 0.08 2.34% -87.47%
MannKind 4.19 0.07 1.58% -16.13%
Merck & Co 92.97 -0.16 -0.17% 19.01%
Moderna Inc 168.97 9.41 5.90% -27.42%
Novartis 81.90 0.68 0.84% -2.63%
Puma Biotechnology 2.79 0.01 0.36% -66.22%
PTC Therapeutics 43.62 0.71 1.65% -0.95%
Ultragenyx Pharmaceutical 64.70 1.32 2.07% -27.82%
Regulus Therapeutics 2.07 0.06 2.99% 185.32%
Sarepta Therapeutics 75.97 0.23 0.30% 5.53%
Thermo Fisher Scientific 554.70 -1.34 -0.24% 6.96%
United Therapeutics 241.90 4.75 2.00% 29.37%
Vanda Pharmaceuticals 11.69 0.19 1.65% -42.10%

Indexes Price Day Year
USND 11533 171.21 1.51% -20.79%
US2000 1763 35.58 2.06% -21.00%

Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of treatments for human diseases. The Company's drug programs include Sotagliflozin, LX9211 and LX2761. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.